4th Sep 2020 15:42
PureTech Health PLC - biotherapeutics company - Says its founded entity Gelesis announced it will deliver one oral presentation and two poster presentations showcasing notable efficacy data for Plenity at the European and International Congress on obesity. The notable data to be presented in the oral presentation are from a subgroup analysis from Glow, a pivotal weight loss study, assessing the safety and efficacy of Plenity in study participants reaching a body mass index of less than 27 kilograms per square metre. After achieving this, participants continued Plenity treatment for an average of 60 days. The overall safety and tolerability profile of Plenity within this group was no different from placebo.
Current stock price: 270.33 pence
Year-to-date change: down 15%
By Evelina Grecenko; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
PureTech